Published in Cancer Res on June 01, 2006
FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res (2010) 1.78
Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol (2009) 1.09
FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res (2012) 1.05
Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate (2013) 1.04
Association of genetic variation in mitotic kinases with breast cancer risk. Breast Cancer Res Treat (2009) 1.02
Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit (2012) 1.01
New combination therapies with cell-cycle agents. Curr Opin Investig Drugs (2008) 0.98
4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1. Cell Cycle (2012) 0.98
High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888. PLoS One (2011) 0.97
Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol (2010) 0.95
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Br J Cancer (2013) 0.88
Mitosis as an anti-cancer drug target. Chromosoma (2013) 0.88
Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS One (2013) 0.87
Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia (2008) 0.87
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget (2013) 0.86
Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development. FASEB J (2014) 0.84
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. Invest New Drugs (2015) 0.79
Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget (2014) 0.79
OTOTOXIC EFFECTS OF CARBOPLATIN IN ORGANOTYPIC CULTURES IN CHINCHILLAS AND RATS. J Otol (2012) 0.77
lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Mol Ther (2017) 0.77
Therapeutic relevance of the protein phosphatase 2A in cancer. Oncotarget (2016) 0.76
Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition. Oncotarget (2015) 0.76
Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. Mol Cell Biol (2016) 0.75
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Polo-like kinases and oncogenesis. Oncogene (2005) 2.86
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol (2008) 2.37
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst (2008) 2.35
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 2.25
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst (2008) 2.20
Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle (2010) 2.18
Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol (2005) 1.99
Brief report: tracheal intubation using the Bonfils intubation fibrescope or direct laryngoscopy for patients with a simulated difficult airway. Can J Anaesth (2008) 1.82
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol (2004) 1.82
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol (2012) 1.75
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle (2009) 1.75
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene (2004) 1.55
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat (2011) 1.53
Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem (2004) 1.52
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene (2002) 1.48
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48
Effect of humidified and heated CO2 during gynecologic laparoscopic surgery on analgesic requirements and postoperative pain. J Am Assoc Gynecol Laparosc (2004) 1.48
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol (2006) 1.44
Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat (2009) 1.38
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol (2010) 1.33
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol (2002) 1.32
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res (2008) 1.31
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia (2005) 1.31
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst (2004) 1.29
T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity (2010) 1.29
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist (2012) 1.29
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast (2004) 1.21
Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials (2006) 1.20
SATB1 gene expression and breast cancer prognosis. Breast (2010) 1.18
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer (2011) 1.16
Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis (2009) 1.15
Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1. Mol Cell Biol (2010) 1.13
Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target. Oncotarget (2011) 1.13
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res (2009) 1.12
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun (2011) 1.12
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol (2006) 1.12
Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle (2006) 1.10
Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res (2006) 1.09
Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target (2004) 1.08
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res (2007) 1.07
Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol (2002) 1.06
A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem (2009) 1.04
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 1.03
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One (2011) 1.03
Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem (2005) 1.03
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer (2008) 1.03
The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer (2005) 1.00
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle (2007) 1.00
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem (2008) 1.00
A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget (2012) 0.99
Uterine contractility and directed sperm transport assessed by hysterosalpingoscintigraphy (HSSG) and intrauterine pressure (IUP) measurement. Acta Obstet Gynecol Scand (2004) 0.99
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res (2005) 0.98
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Cell Cycle (2013) 0.97
Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis. Eur J Cancer (2008) 0.96